{"title":"Global trends in retinal vein occlusion studies from 2004 to 2023: a bibliometric analysis.","authors":"Meng-Sha Sun, Hong-Ping Cui, Jian-Cen Tang","doi":"10.18240/ijo.2025.09.18","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To analyse the research status and explore global trends in retinal vein occlusion (RVO) studies.</p><p><strong>Methods: </strong>Publications related to RVO from 2004 to 2023 were extracted from the Web of Science Core Collection (WoSCC). Variables including the number of publications, as well as countries, organizations, authors, journals, references and keywords were analysed using Bibliometrix-BilioShiny. Data visualization was performed using VOSviewer and CiteSpace.</p><p><strong>Results: </strong>A total of 4848 publications were retrieved, and generally, the number of publications showed an overall increasing trend with slight fluctuations over the past 20y. The country with the most publications was the United States. The journal with the most publications was <i>Retina</i>, and the most cited journal was <i>Ophthalmology</i>. The most prolific organization was the University of California, Los Angeles. The most productive author was Noma H, and the most cited author was Campochiaro PA. The top co-cited references mainly focused on the prevalence of RVO and the therapies used in clinical trials. According to the co-occurrence analysis, the keywords formed 3 clusters: 1) risk factors and pathogenesis of RVO, 2) treatments of RVO, and 3) imaging diagnosis of RVO. Anti-vascular endothelial growth factor (VEGF) treatments and artificial intelligence have recently become popular research topics.</p><p><strong>Conclusion: </strong>Bibliometric analysis of the research status and trends of RVO could provide researchers and clinicians with valuable insights for further collaboration, future research directions, and clinical practice.</p>","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 9","pages":"1759-1769"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378686/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.09.18","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To analyse the research status and explore global trends in retinal vein occlusion (RVO) studies.
Methods: Publications related to RVO from 2004 to 2023 were extracted from the Web of Science Core Collection (WoSCC). Variables including the number of publications, as well as countries, organizations, authors, journals, references and keywords were analysed using Bibliometrix-BilioShiny. Data visualization was performed using VOSviewer and CiteSpace.
Results: A total of 4848 publications were retrieved, and generally, the number of publications showed an overall increasing trend with slight fluctuations over the past 20y. The country with the most publications was the United States. The journal with the most publications was Retina, and the most cited journal was Ophthalmology. The most prolific organization was the University of California, Los Angeles. The most productive author was Noma H, and the most cited author was Campochiaro PA. The top co-cited references mainly focused on the prevalence of RVO and the therapies used in clinical trials. According to the co-occurrence analysis, the keywords formed 3 clusters: 1) risk factors and pathogenesis of RVO, 2) treatments of RVO, and 3) imaging diagnosis of RVO. Anti-vascular endothelial growth factor (VEGF) treatments and artificial intelligence have recently become popular research topics.
Conclusion: Bibliometric analysis of the research status and trends of RVO could provide researchers and clinicians with valuable insights for further collaboration, future research directions, and clinical practice.
期刊介绍：
· International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication
and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online).
This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from
WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed,
PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166.
IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific
Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO);
Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President,
Chinese Academy of Engineering.
International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of
blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of
AAO/PAAO) et al.
Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of
Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and
Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society).
Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press).
Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and
Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics).
Associate Editors-in-Chief include:
Prof. Ning-Li Wang (President Elect of APAO);
Prof. Ke Yao (President of Chinese Ophthalmological Society) ;
Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ;
Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA);
Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society);
Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA);
Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA).
IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles,
both basic and clinical papers.
Instruction is Welcome Contribution is Welcome Citation is Welcome
Cooperation organization
International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
